As peptide therapeutics continue their rapid expansion and from GLP-1 receptor agonists to novel oncology peptides and regulatory complexity has grown in lockstep. For companies navigating IND submissions, NDA filings, and FDA meetings, a dedicated regulatory affairs peptide specialist is no longer a luxury. It is a strategic hire that can compress your timeline to approval and protect you from costly missteps. See FDA drug development for reference.
This guide is written for VPs of Regulatory Affairs, General Counsel, and hiring managers at peptide therapeutics companies who need to evaluate this role with precision.
Key Takeaways
- A regulatory affairs peptide specialist bridges peptide-specific chemistry, manufacturing, and controls (CMC) requirements with FDA submission strategy.
- Core deliverables include IND/NDA preparation, FDA meeting management, labeling, and pharmacovigilance oversight.
- RAC certification and direct 21 CFR Part 312/314 experience are the minimum credentialing benchmarks.
- For early-stage companies, outsourcing to a regulatory CRO may be cost-effective until a pipeline matures to Phase II.
- Mid-level specialists command $110,000-$145,000; senior directors exceed $175,000 in major biotech markets.
What a Regulatory Affairs Peptide Specialist Does
This role sits at the intersection of science and regulatory strategy. Unlike a generalist regulatory affairs manager, a peptide specialist brings domain-specific knowledge of how the FDA evaluates peptide-based drug substances and including unique considerations around degradation pathways, immunogenicity, route of administration (injectable vs. oral), and manufacturing comparability.
They translate that technical understanding into submission-ready documentation and serve as the primary liaison between internal teams and the FDA's Center for Drug Evaluation and Research (CDER). In practice, they spend significant time interpreting agency guidance, coordinating cross-functional input from CMC, clinical, and nonclinical teams, and managing the iterative review cycles that define drug development.
"The regulatory pathway for peptide therapeutics requires an understanding of both the small molecule and biologic frameworks and specialists who can navigate that ambiguity are exceptionally rare.", Former CDER Reviewer, FDA Division of Metabolism and Endocrinology Products (2024)
Core Responsibilities
IND and NDA Submissions
The most time-intensive deliverable. A regulatory affairs peptide specialist leads preparation of Investigational New Drug (IND) applications under 21 CFR Part 312 and New Drug Applications (NDAs) under 21 CFR Part 314. For peptides, this includes detailed CMC modules covering synthesis route, impurity profiling, stability data, and container closure systems. They also manage annual IND reports and safety updates to maintain application currency throughout clinical development.
Per FDA's CDER guidance on drug applications, incomplete or inconsistent CMC data is among the most common causes of Refuse to File (RTF) actions and making submission quality directly tied to timeline and cost outcomes.
FDA Meeting Management
Pre-IND, Type B, and Type C meetings require careful preparation of briefing documents, structured question lists, and post-meeting minutes. The specialist manages the full lifecycle of these interactions, ensuring the company enters each meeting with a defensible position and leaves with clear agency alignment. Mishandling these touchpoints and either by asking premature questions or failing to document agency commitments and can introduce months of uncertainty into the program.
Labeling Strategy
Labeling for peptide therapeutics involves coordinating proposed prescribing information (PI) with clinical pharmacology, safety, and commercial teams. The specialist ensures labeling claims are supported by the data package, anticipates FDA reviewer concerns, and manages the back-and-forth of labeling negotiations during the review cycle.
Pharmacovigilance Oversight
Post-approval, the role expands to monitoring adverse event reporting obligations, managing MedWatch submissions, and supporting REMS development where required. For companies with multiple peptide assets, building a structured pharmacovigilance framework early and before approval and prevents downstream compliance gaps.
Required Qualifications
The minimum credentialing standard for this role is RAC (Regulatory Affairs Certification) from the Regulatory Affairs Professionals Society (RAPS), combined with demonstrated hands-on experience with 21 CFR Parts 312 and 314. Candidates with prior CDER experience or who have navigated at least one IND to NDA transition in a peptide or closely adjacent therapeutic category carry meaningfully less ramp-up risk.
Additional qualifications to prioritize:
- Familiarity with FDA's peptide-specific guidance, including the 2019 CDER guidance on drug products that are or may be subject to compounding
- Experience with eCTD submission systems (Lorenz, Veeva Vault RIM, or equivalent)
- Understanding of ICH Q3A/Q3B impurity guidelines as applied to synthetic peptides
- Exposure to EU regulatory frameworks (EMA) if the company has or anticipates international programs
For more context on adjacent staffing needs within the clinical development function, see our guide on peptide clinical trial staffing.
When to Hire vs. Outsource
Hire full-time when:
- You have two or more active INDs or a lead asset approaching Phase II
- You have ongoing FDA dialogue that requires institutional memory and continuity
- Your pipeline is primarily peptide-focused, meaning domain expertise will compound over time
Outsource when:
- You are pre-IND with a single asset and do not yet have the infrastructure to support a senior hire
- You need surge capacity for a specific submission deliverable without a long-term headcount commitment
- You are evaluating regulatory strategy before committing to a full development program
Regulatory CROs with peptide-specific experience can cover early-stage submissions effectively. However, once you enter active agency dialogue, the absence of an internal owner creates coordination risk that compounds quickly.
For companies scaling their operations teams simultaneously, our resources on GMP peptide manufacturing staff and peptide research coordinator roles address adjacent workforce decisions.
Salary Benchmarks
Compensation varies by geography, pipeline stage, and the depth of FDA submission experience. As of 2026:
| Level | Typical Salary Range |
|---|---|
| Regulatory Affairs Specialist (3-6 years) | $110,000, $145,000 |
| Senior Regulatory Affairs Manager (6-10 years) | $145,000, $175,000 |
| Director, Regulatory Affairs (10+ years) | $175,000, $220,000+ |
San Diego, Boston, and the San Francisco Bay Area carry 10-20% premiums over national averages. Remote-eligible roles have modestly compressed those geographic differentials, though senior director-level positions with active FDA meeting responsibilities often still require proximity to company headquarters.
Equity is standard at the director level and above. For companies at Series B or later, total compensation packages routinely include 0.1-0.5% equity, particularly for first regulatory hires.
Frequently Asked Questions
What is the difference between a regulatory affairs specialist and a regulatory affairs director at a peptide company?
A specialist executes submission tasks under the oversight of a director or VP and writing CTD modules, compiling briefing documents, tracking FDA correspondence. A director owns the regulatory strategy, manages agency relationships directly, and often carries budget responsibility. Early-stage companies frequently hire at the director level first to get strategic oversight, then build out execution capacity below that role.
Does a regulatory affairs peptide specialist need a scientific degree?
Most hiring managers require at minimum a B.S. in a life sciences discipline; advanced degrees (M.S., Ph.D., or Pharm.D.) are strongly preferred at the director level. What differentiates strong candidates is not degree level alone but direct experience with the type of data packages FDA expects for synthetic peptide drug substances and particularly CMC modules and stability protocols.
How long does it typically take to hire a qualified regulatory affairs peptide specialist?
Given the specificity of the role, expect a 60-90 day search from initial outreach to offer acceptance for a senior hire. Regulatory affairs talent with direct peptide IND/NDA experience is a narrow candidate pool. Shortening time-to-hire typically requires working with a specialized life sciences recruiting partner and moving quickly through interview stages once a qualified candidate is identified.
Topics
PeptideStaff Editorial Team
Healthcare Staffing Specialists
Collective expertise across clinical staffing, regulatory compliance, and peptide industry operations
Our editorial team combines backgrounds in healthcare recruitment, peptide research, and clinical operations to produce accurate, actionable staffing and industry guidance for peptide businesses.
Reviewed by the PeptideStaff Editorial Team, April 2026